NCT07196696 An in Vivo CT Imaging Study of GMA-Tulip, I-gel, and LMA Supreme (GLAM-II)
| NCT ID | NCT07196696 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Zhejiang Cancer Hospital |
| Condition | Supraglottic Airway Device |
| Study Type | INTERVENTIONAL |
| Enrollment | 9 participants |
| Start Date | 2025-10-12 |
| Primary Completion | 2025-12-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 9 participants in total. It began in 2025-10-12 with a primary completion date of 2025-12-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Laryngeal masks are core devices for supraglottic airway management, and the accuracy of their anatomical position directly impacts ventilation safety and the incidence of complications. Despite their wide clinical application, gaps remain in understanding their in vivo anatomical characteristics. This study aims to evaluate the in vivo anatomical features (e.g., insertion depth, anatomical alignment, tissue compression) of three laryngeal masks (LMA Supreme, I-gel, GMA-Tulip) using CT scanning in anesthetized patients undergoing CT interventional therapy, providing anatomical evidence for optimized laryngeal mask selection and complication prevention.
Eligibility Criteria
Inclusion Criteria: * Aged 18-75 years, scheduled for CT interventional therapy; * Aged 18-75 years, scheduled for CT interventional therapy; * Body Mass Index (BMI) \<30 kg/m²; * Good communication and cooperation, with voluntary signing of the informed consent form. Exclusion Criteria: * Presence of head/neck or airway anatomical abnormalities (e.g., laryngeal cartilage malformation, Grade III tonsillar hypertrophy, tongue hypertrophy, cervical spine malformation) that may affect laryngeal mask insertion or CT imaging evaluation; * Current participation in other clinical studies.
Contact & Investigator
Jiangling Wang, Dr
PRINCIPAL INVESTIGATOR
Zhejiang Cancer Hospital
Frequently Asked Questions
Who can join the NCT07196696 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Supraglottic Airway Device. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07196696 currently recruiting?
Yes, NCT07196696 is actively recruiting participants. Contact the research team at ec@zjcc.org.cn for enrollment information.
Where is the NCT07196696 trial being conducted?
This trial is being conducted at Hangzhou, China, Hangzhou, China.
Who is sponsoring the NCT07196696 clinical trial?
NCT07196696 is sponsored by Zhejiang Cancer Hospital. The principal investigator is Jiangling Wang, Dr at Zhejiang Cancer Hospital. The trial plans to enroll 9 participants.